nach oben

Erschienen in:

01.01.2024 | Research

Assessing bone formation on hydrophilic and hydrophobic implant surfaces in a murine model treated with bisphosphonates

verfasst von: Julio Cesar Sánchez-Puetate, Bruno Luís Graciliano Silva, Felipe Eduardo Pinotti, Camila Chierici Marcantonio, Guilherme José Pimentel Lopes de Oliveira, Elcio Marcantonio Junior, Rosemary Adriana Chierici Marcantonio

Erschienen in: Clinical Oral Investigations | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the osseointegration of implants with hydrophobic (HFB) and hydrophilic (HFL) surfaces in a murine model of high-dose bisphosphonates (BPs).

Materials and methods

Sixty-four rats were randomly allocated into four groups: control group with HFB implants (CG-HFB), control group with HFL implants (CG-HFL), BP group with HFB implants (BP-HFB), and BP group with HFL implants (BP-HFL). Animals were euthanized after 15 and 45 days (n=8). The dependent variables assessed were the removal torque (biomechanical analysis), the bone volume around the implants (%BV/TV) (microtomographic analysis), the bone-implant contact (%BIC), the bone between the threads (%BBT) (histomorphometric analysis), and the expression of bone metabolism markers (immunohistochemistry analysis).

Results

The CG-HFL and BP-HFL groups presented higher removal torque than the CG-HFB and BP-HFB implants. The %BIC of the CG-HFL surfaces was slightly higher than that of the CG-HFB implants. The BP-HFB and BP-HFL groups presented a higher %BIC than that of the CG-HFB and CG-HFL groups (p<0.001). BP therapy also increased the %BBT at both implant surfaces. Higher levels of ALP were observed in the matrix region of bone tissue on the HFL surfaces than on the HFB surfaces.

Conclusion

Both surfaces enable osseointegration in rats under BP therapy.

Clinical relevance

The study demonstrates that hydrophobic (HFB) and hydrophilic (HFL) implant surfaces can promote osseointegration in rats undergoing bisphosphonate therapy. The HFL surfaces exhibited improved biomechanical performance, higher bone-implant contact, and increased bone volume, suggesting their potential clinical relevance for implant success in individuals on bisphosphonate treatment.

Bosshardt DD, Chappuis V, Buser D (2017) Osseointegration of titanium, titanium alloy and zirconia dental implants: current knowledge and open questions. Periodontol 73:22–40. https://doi.org/10.1111/prd.12179CrossRef

Lane NE (2006) Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 194:S3–S11. https://doi.org/10.1016/j.ajog.2005.08.047CrossRefPubMed

Tolia M, Zygogianni A, Kouvaris JR, Meristoudis C, Margari N, Karakitsos P, Kokakis I, Kardamakis D, Papadimitriou C, Mystakidou K, Tsoukalas N, Kyrgias G, Armonis B, Filippiadis DK, Kelekis AD, Kelekis N, Kouloulias V (2014) The key role of bisphosphonates in the supportive care of cancer patients. Anticancer Res 34:23–37PubMed

Conte Neto N, Spolidorio LC, Andrade CR, Bastos AS, Guimaraes M, Marcantonio E Jr (2013) Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents. Int J Exp Pathol 94:65–73. https://doi.org/10.1111/iep.12007CrossRefPubMedPubMedCentral

Tella SH, Gallagher JC (2014) Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142:155–170. https://doi.org/10.1016/j.jsbmb.2013.09.008CrossRefPubMed

Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478–1487. https://doi.org/10.1002/jbmr.5650101008CrossRefPubMed

Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA (1999) Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 274:34967–34973. https://doi.org/10.1074/jbc.274.49.34967CrossRefPubMed

Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW and Bijvoet OL (1986) Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1:27-39.PubMed

Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, Patella V, Zambonin Zallone A, Grano M (1998) Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 63:230–235. https://doi.org/10.1007/s002239900519CrossRefPubMed

10.

Flanagan AM, Chambers TJ (1991) Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407–415. https://doi.org/10.1007/BF02555852CrossRefPubMed

11.

Piper K, Boyde A, Jones SJ (1994) The effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP) on the resorptive function of osteoclasts of known nuclear number. Calcif Tissue Int 54:56–61. https://doi.org/10.1007/BF00316291CrossRefPubMed

12.

Maruotti N, Corrado A, Neve A, Cantatore FP (2012) Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol 68:1013–1018. https://doi.org/10.1007/s00228-012-1216-7CrossRefPubMed

13.

Ohe JY, Kwon YD, Lee HW (2012) Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. Clin Oral Investig 16:1153–1159. https://doi.org/10.1007/s00784-011-0614-zCrossRefPubMed

14.

Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680–686. https://doi.org/10.1006/bbrc.2002.6510CrossRefPubMed

15.

Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s–6230s. https://doi.org/10.1158/1078-0432.CCR-06-0843CrossRefPubMed

16.

Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544PubMed

17.

Ledoux D, Hamma-Kourbali Y, Di Benedetto M, Foucault-Bertaud A, Oudar O, Sainte-Catherine O, Lecouvey M, Kraemer M (2006) A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice. Anti-Cancer Drugs 17:479–485. https://doi.org/10.1097/01.cad.0000198909.52701.0fCrossRefPubMed

18.

Santini D, Vincenzi B, Di Cuonzo G, Battistoni F, Gravasci M, Fossati C, Avvisati G, Denaro V, Campisi C, Tonini G (2001) Pamidronate (P) induces modifications of circulating angiogenetic factors in cancer patients. Eur J Cancer 37:S262–S263. https://doi.org/10.1016/s0959-8049(01)81465-9CrossRef

19.

Vincenzi B, Santini D, Rocci L, Tonini G (2003) Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann Oncol 14:806–807. https://doi.org/10.1093/annonc/mdg194CrossRefPubMed

20.

Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, Blair HC, Roodman GD (2010) Osteoclasts are important for bone angiogenesis. Blood 115:140–149. https://doi.org/10.1182/blood-2009-08-237628CrossRefPubMedPubMedCentral

21.

Kapitola J, Zak J (1998) Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res 47:237–240PubMed

22.

Rogers JP, Stewart PR, Stapleton JV, Hribar DL, Adams P, Gale AE (2000) An interdisciplinary approach to the management of complex medical and dental conditions. Aust Dent J 45:270–276. https://doi.org/10.1111/j.1834-7819.2000.tb00262.xCrossRefPubMed

23.

Tella SH, Gallagher JC (2014) Biological agents in management of osteoporosis. Eur J Clin Pharmacol 70:1291–1301. https://doi.org/10.1007/s00228-014-1735-5CrossRefPubMed

24.

Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM (2008) Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13:911–920. https://doi.org/10.1634/theoncologist.2008-0091CrossRefPubMed

25.

Kellesarian SV, Abduljabbar T, Vohra F, Malignaggi VR, Malmstrom H, Romanos GE, Javed F (2017) Role of local alendronate delivery on the osseointegration of implants: a systematic review and meta-analysis. Int J Oral Maxillofac Surg 46:912–921. https://doi.org/10.1016/j.ijom.2017.03.009CrossRefPubMed

26.

Yajima N, Munakata M, Fuchigami K, Sanda M, Kasugai S (2017) Influence of bisphosphonates on implant failure rates and characteristics of postmenopausal woman mandibular jawbone. J Oral Implantol 43:345–349. https://doi.org/10.1563/aaid-joi-D-17-00015CrossRefPubMed

27.

Malden N, Lopes V (2012) An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab 30:171–182. https://doi.org/10.1007/s00774-011-0299-zCrossRefPubMed

28.

Qi WX, Tang LN, He AN, Yao Y, Shen Z (2014) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 19:403–410. https://doi.org/10.1007/s10147-013-0561-6CrossRefPubMed

29.

Hallmer F, Andersson G, Gotrick B, Warfvinge G, Anderud J, Bjornland T (2018) Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol 126:477–485. https://doi.org/10.1016/j.oooo.2018.08.015CrossRefPubMed

30.

Verzola MH, Frizzera F, de Oliveira GJ, Pereira RM, Rodrigues-Filho UP, Nonaka KO, Orrico SR (2015) Effects of the long-term administration of alendronate on the mechanical properties of the basal bone and on osseointegration. Clin Oral Implants Res 26:1466–1475. https://doi.org/10.1111/clr.12492CrossRefPubMed

31.

Cohen DJ, Lohmann CH, Scott KM, Olson LC, Boyan BD, Schwartz Z (2022) Osseointegration and remodeling of mineralized bone graft are negatively impacted by prior treatment with bisphosphonates. J Bone Joint Surg Am 104:1750–1759. https://doi.org/10.2106/JBJS.21.01489CrossRefPubMed

32.

Frizzera F, Verzola MHA, de Molon RS, de Oliveira G, Giro G, Spolidorio LC, Pereira RMR, Tetradis S, Cirelli JA, Orrico SRP (2019) Evaluation of bone turnover after bisphosphonate withdrawal and its influence on implant osseointegration: an in vivo study in rats. Clin Oral Investig 23:1733–1744. https://doi.org/10.1007/s00784-018-2612-xCrossRefPubMed

33.

Oh KC, Moon HS, Lee JH, Park YB, Kim JH (2015) Effects of alendronate on the peri-implant bone in rats. Oral Dis 21:248–256. https://doi.org/10.1111/odi.12258CrossRefPubMed

34.

Yu RQ, Wang JY, Rao NJ, Huo L, Zheng LW (2021) Effects of Bisphosphonates on osseointegration of dental implants in rabbit model. Biomed Res Int 2021:6689564. https://doi.org/10.1155/2021/6689564CrossRefPubMedPubMedCentral

35.

Prisinoto NR, Molon RS, Scardueli CR, Spin-Neto R, Marcantonio RAC, Oliveira G (2020) Alendronate impairs healing of calvaria critical defects after bone graft with different bone substitute materials. J Oral Maxillofac Surg 78:2184–2194. https://doi.org/10.1016/j.joms.2020.08.022CrossRefPubMed

36.

Buser D, Broggini N, Wieland M, Schenk RK, Denzer AJ, Cochran DL, Hoffmann B, Lussi A, Steinemann SG (2004) Enhanced bone apposition to a chemically modified SLA titanium surface. J Dent Res 83:529–533. https://doi.org/10.1177/154405910408300704CrossRefPubMed

37.

Sartoretto SC, Alves AT, Resende RF, Calasans-Maia J, Granjeiro JM, Calasans-Maia MD (2015) Early osseointegration driven by the surface chemistry and wettability of dental implants. J Appl Oral Sci 23:279–287. https://doi.org/10.1590/1678-775720140483CrossRefPubMedPubMedCentral

38.

Pinotti FE, de Oliveira G, Aroni MAT, Marcantonio RAC, Marcantonio E Jr (2018) Analysis of osseointegration of implants with hydrophilic surfaces in grafted areas: A Preclinical study. Clin Oral Implants Res 29:963–972. https://doi.org/10.1111/clr.13361CrossRefPubMed

39.

Pinotti FE, Aron MAT, Oliveira G, Marcantonio Junior E, Marcantonio RAC (2022) Implants with hydrophilic surfaces equalize the osseointegration of implants in normo- and hyperglycaemic rats. Braz Dent J 33:71–77. https://doi.org/10.1590/0103-6440202204793CrossRefPubMedPubMedCentral

40.

de Oliveira GJ, de Paula LG, Spin-Neto R, Stavropoulos A, Spolidorio LC, Marcantonio E Jr, Marcantonio RA (2014) Effect of avocado/soybean unsaponifiables on osseointegration: a proof-of-principle preclinical in vivo study. Int J Oral Maxillofac Implants 29:949–957. https://doi.org/10.11607/jomi.3498CrossRefPubMed

41.

Lang NP, Salvi GE, Huynh-Ba G, Ivanovski S, Donos N, Bosshardt DD (2011) Early osseointegration to hydrophilic and hydrophobic implant surfaces in humans. Clin Oral Implants Res 22:349–356. https://doi.org/10.1111/j.1600-0501.2011.02172.xCrossRefPubMed

42.

Lee RSB, Hamlet SM, Ivanovski S (2017) The influence of titanium surface characteristics on macrophage phenotype polarization during osseous healing in type I diabetic rats: a pilot study. Clin Oral Implants Res 28:e159–e168. https://doi.org/10.1111/clr.12979CrossRefPubMed

43.

Calciolari E, Mardas N, Dereka X, Anagnostopoulos AK, Tsangaris GT, Donos N (2018) Protein expression during early stages of bone regeneration under hydrophobic and hydrophilic titanium domes. A pilot study. J Periodontal Res 53:174–187. https://doi.org/10.1111/jre.12498CrossRefPubMed

44.

Pinotti FE, Aroni MAT, Oliveira G, Silva BLG, Marcantonio Junior E, Marcantonio RAC (2023) Osseointegration of implants with superhydrophilic surfaces in rats with high serum levels of nicotine. Braz Dent J 34:105–112. https://doi.org/10.1590/0103-6440202305096CrossRefPubMedPubMedCentral

45.

Karlsson J, Martinelli A, Fathali HM, Bielecki J, Andersson M (2016) The effect of alendronate on biomineralization at the bone/implant interface. J Biomed Mater Res A 104:620–629. https://doi.org/10.1002/jbm.a.35602CrossRefPubMed

46.

Abtahi J, Tengvall P, Aspenberg P (2012) A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. Bone 50:1148–1151. https://doi.org/10.1016/j.bone.2012.02.001CrossRefPubMed

47.

Corrado A, Neve A, Maruotti N, Gaudio A, Marucci A, Cantatore FP (2010) Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures. Clin Exp Rheumatol 28:873–879PubMed

48.

Ma X, Xu Z, Ding S, Yi G, Wang Q (2018) Alendronate promotes osteoblast differentiation and bone formation in ovariectomy-induced osteoporosis through interferon-beta/signal transducer and activator of transcription 1 pathway. Exp Ther Med 15:182–190. https://doi.org/10.3892/etm.2017.5381CrossRefPubMed

49.

Orimo H (2010) The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch 77:4–12. https://doi.org/10.1272/jnms.77.4CrossRefPubMed

50.

Wehner C, Lettner S, Moritz A, Andrukhov O, Rausch-Fan X (2020) Effect of bisphosphonate treatment of titanium surfaces on alkaline phosphatase activity in osteoblasts: a systematic review and meta-analysis. Bmc Oral Health 20:125. https://doi.org/10.1186/s12903-020-01089-4CrossRefPubMedPubMedCentral

51.

Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575. https://doi.org/10.1016/j.joms.2005.07.010CrossRefPubMed

52.

Wang JY, Huo L, Yu RQ, Rao NJ, Lu WW, Zheng LW (2019) Skeletal site-specific response of jawbones and long bones to surgical interventions in rats treated with zoledronic acid. Biomed Res Int 2019:5138175. https://doi.org/10.1155/2019/5138175CrossRefPubMedPubMedCentral

53.

Ayan M, Dolanmaz D, Mihmanli A, Ayan A, Kurkcu M (2012) The effect of systemically administrated zoledronic acid on the osseointegration of dental implants. Oral Dis 18:802–808. https://doi.org/10.1111/j.1601-0825.2012.01948.xCrossRefPubMed

54.

Giro G, Coelho PG, Pereira RM, Jorgetti V, Marcantonio E Jr, Orrico SR (2011) The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants. Clin Oral Implants Res 22:259–264. https://doi.org/10.1111/j.1600-0501.2010.01989.xCrossRefPubMed

55.

Apostu D, Lucaciu O, Mester A, Oltean-Dan D, Gheban D, Rares Ciprian Benea H (2020) Tibolone, alendronate, and simvastatin enhance implant osseointegration in a preclinical in vivo model. Clin Oral Implants Res 31:655–668. https://doi.org/10.1111/clr.13602CrossRefPubMed

56.

Cardemil C, Omar OM, Norlindh B, Wexell CL, Thomsen P (2013) The effects of a systemic single dose of zoledronic acid on post-implantation bone remodelling and inflammation in an ovariectomised rat model. Biomaterials 34:1546–1561. https://doi.org/10.1016/j.biomaterials.2012.11.003CrossRefPubMed

57.

Hou M, Lee RSB, Du Z, Hamlet SM, Vaquette C, Ivanovski S (2019) The influence of high-dose systemic zoledronate administration on osseointegration of implants with different surface topography. J Periodontal Res 54:633–643. https://doi.org/10.1111/jre.12664CrossRefPubMed

58.

Bohner L, Meier N, Gremse F, Tortamano P, Kleinheinz J, Hanisch M (2020) Magnetic resonance imaging artifacts produced by dental implants with different geometries. Dentomaxillofac Radiol 49:20200121. https://doi.org/10.1259/dmfr.20200121CrossRefPubMedPubMedCentral

59.

He T, Cao C, Xu Z, Li G, Cao H, Liu X, Zhang C, Dong Y (2017) A comparison of micro-CT and histomorphometry for evaluation of osseointegration of PEO-coated titanium implants in a rat model. Sci Rep 7:16270. https://doi.org/10.1038/s41598-017-16465-4CrossRefPubMedPubMedCentralADS

60.

Zancanela DC, Simaa AM, Matsubara EY, Rosolen JM, Ciancaglini P (2016) Defective multilayer carbon nanotubes increase alkaline phosphatase activity and bone-like nodules in osteoblast cultures. J Nanosci Nanotechnol 16:1437–1444. https://doi.org/10.1166/jnn.2016.10753CrossRefPubMed

61.

Al Hadi H, Smerdon GR, Fox SW (2015) Hyperbaric oxygen therapy accelerates osteoblast differentiation and promotes bone formation. J Dent 43:382–388. https://doi.org/10.1016/j.jdent.2014.10.006CrossRefPubMed

Titel: Assessing bone formation on hydrophilic and hydrophobic implant surfaces in a murine model treated with bisphosphonates
verfasst von: Julio Cesar Sánchez-Puetate
Bruno Luís Graciliano Silva
Felipe Eduardo Pinotti
Camila Chierici Marcantonio
Guilherme José Pimentel Lopes de Oliveira
Elcio Marcantonio Junior
Rosemary Adriana Chierici Marcantonio
Publikationsdatum: 01.01.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Oral Investigations / Ausgabe 1/2024
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-023-05480-7

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Assessing bone formation on hydrophilic and hydrophobic implant surfaces in a murine model treated with bisphosphonates